Show simple item record

dc.contributor.authorBrugge, W. R.
dc.contributor.authorLauwers, Gregory Yves
dc.contributor.authorSchoellhammer, Carl Magnus
dc.contributor.authorZervas, Michael J.
dc.contributor.authorTraverso, Carlo Giovanni
dc.contributor.authorAnderson, Daniel Griffith
dc.contributor.authorLanger, Robert S
dc.contributor.authorMaa, Ruby C.
dc.contributor.authorSchroeder, Avraham Dror
dc.contributor.authorBarman, Ross
dc.contributor.authorDiCiccio, Angela M
dc.contributor.authorSwiston, Albert J., Jr.
dc.contributor.authorBlankschtein, Daniel
dc.date.accessioned2017-04-13T20:03:20Z
dc.date.available2017-04-13T20:03:20Z
dc.date.issued2015-10
dc.identifier.issn1946-6234
dc.identifier.issn1946-6242
dc.identifier.urihttp://hdl.handle.net/1721.1/108145
dc.descriptionavailable in PMC 2016 April 08en_US
dc.description.abstractThere is a significant clinical need for rapid and efficient delivery of drugs directly to the site of diseased tissues for the treatment of gastrointestinal (GI) pathologies, in particular, Crohn’s and ulcerative colitis. However, complex therapeutic molecules cannot easily be delivered through the GI tract because of physiologic and structural barriers. We report the use of ultrasound as a modality for enhanced drug delivery to the GI tract, with an emphasis on rectal delivery. Ultrasound increased the absorption of model therapeutics inulin, hydrocortisone, and mesalamine two- to tenfold in ex vivo tissue, depending on location in the GI tract. In pigs, ultrasound induced transient cavitation with negligible heating, leading to an order of magnitude enhancement in the delivery of mesalamine, as well as successful systemic delivery of a macromolecule, insulin, with the expected hypoglycemic response. In a rodent model of chemically induced acute colitis, the addition of ultrasound to a daily mesalamine enema (compared to enema alone) resulted in superior clinical and histological scores of disease activity. In both animal models, ultrasound treatment was well tolerated and resulted in minimal tissue disruption, and in mice, there was no significant effect on histology, fecal score, or tissue inflammatory cytokine levels. The use of ultrasound to enhance GI drug delivery is safe in animals and could augment the efficacy of GI therapies and broaden the scope of agents that could be delivered locally and systemically through the GI tract for chronic conditions such as inflammatory bowel disease.en_US
dc.description.sponsorshipUnited States. National Institutes of Health (EB-00351)en_US
dc.description.sponsorshipUnited States. National Institutes of Health (EB-000244)en_US
dc.description.sponsorshipUnited States. National Institutes of Health (CA014051)en_US
dc.description.sponsorshipUnited States. National Institutes of Health (T32-DK007191-38-S1)en_US
dc.language.isoen_US
dc.publisherAmerican Association for the Advancement of Science (AAAS)en_US
dc.relation.isversionofhttp://dx.doi.org/10.1126/scitranslmed.aaa5937en_US
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.en_US
dc.sourcePMCen_US
dc.titleUltrasound-mediated gastrointestinal drug deliveryen_US
dc.typeArticleen_US
dc.identifier.citationSchoellhammer, C. M., A. Schroeder, R. Maa, G. Y. Lauwers, A. Swiston, M. Zervas, R. Barman, et al. “Ultrasound-Mediated Gastrointestinal Drug Delivery.” Science Translational Medicine 7, no. 310 (October 21, 2015): 310ra168–310ra168.en_US
dc.contributor.departmentMassachusetts Institute of Technology. Institute for Medical Engineering & Scienceen_US
dc.contributor.departmentHarvard University--MIT Division of Health Sciences and Technologyen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Chemical Engineeringen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Mechanical Engineeringen_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.mitauthorSchoellhammer, Carl Magnus
dc.contributor.mitauthorSwiston Jr, Albert J.
dc.contributor.mitauthorZervas, Michael J.
dc.contributor.mitauthorTraverso, Carlo Giovanni
dc.contributor.mitauthorAnderson, Daniel Griffith
dc.contributor.mitauthorBlankschtein, Edmundo D
dc.contributor.mitauthorLanger, Robert S
dc.contributor.mitauthorMaa, Ruby C.
dc.contributor.mitauthorSchroeder, Avraham Dror
dc.contributor.mitauthorBarman, Ross
dc.contributor.mitauthorDiCiccio, Angela M
dc.relation.journalScience Translational Medicineen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsSchoellhammer, Carl M.; Schroeder, Avi; Maa, Ruby; Lauwers, Gregory Yves; Swiston, Albert; Zervas, Michael; Barman, Ross; DiCiccio, Angela M.; Brugge, William R.; Anderson, Daniel G.; Blankschtein, Daniel; Langer, Robert; Traverso, Giovannien_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0001-6694-6761
dc.identifier.orcidhttps://orcid.org/0000-0002-6410-3784
dc.identifier.orcidhttps://orcid.org/0000-0002-4260-2785
dc.identifier.orcidhttps://orcid.org/0000-0001-5629-4798
dc.identifier.orcidhttps://orcid.org/0000-0002-7836-415X
dc.identifier.orcidhttps://orcid.org/0000-0003-4255-0492
mit.licensePUBLISHER_POLICYen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record